Glenmark Pharmaceuticals Limited (NSE: GLENMARK)
India
· Delayed Price · Currency is INR 1,466.40
-26.25 (-1.76%)
Nov 21, 2024, 3:30 PM IST
Glenmark Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 122,777 | 118,131 | 115,832 | 123,049 | 109,439 | 106,410 | Upgrade
|
| Other Revenue | 8,022 | 8,323 | 723.29 | - | - | 162.93 | Upgrade
|
| Revenue | 130,799 | 126,454 | 116,556 | 123,049 | 109,439 | 106,573 | Upgrade
|
| Revenue Growth (YoY) | -4.88% | 8.49% | -5.28% | 12.44% | 2.69% | 8.03% | Upgrade
|
| Cost of Revenue | 43,735 | 45,789 | 44,108 | 45,481 | 38,470 | 38,487 | Upgrade
|
| Gross Profit | 87,064 | 80,665 | 72,448 | 77,568 | 70,970 | 68,085 | Upgrade
|
| Selling, General & Admin | 35,293 | 34,465 | 31,833 | 29,176 | 28,103 | 28,627 | Upgrade
|
| Other Operating Expenses | 28,361 | 25,694 | 23,541 | 25,124 | 21,271 | 22,303 | Upgrade
|
| Operating Expenses | 69,248 | 66,208 | 61,066 | 59,168 | 53,809 | 55,102 | Upgrade
|
| Operating Income | 17,816 | 14,457 | 11,382 | 18,400 | 17,160 | 12,984 | Upgrade
|
| Interest Expense | -3,710 | -5,160 | -3,490 | -2,981 | -3,531 | -3,773 | Upgrade
|
| Interest & Investment Income | 61.78 | 61.78 | 73.52 | 97.85 | 29.97 | 53.76 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 2,035 | 880.54 | -752.09 | 1,379 | Upgrade
|
| Other Non Operating Income (Expenses) | 494.9 | - | - | 688.35 | 468.65 | - | Upgrade
|
| EBT Excluding Unusual Items | 14,663 | 9,359 | 10,000 | 17,086 | 13,376 | 10,644 | Upgrade
|
| Gain (Loss) on Sale of Assets | 15.3 | 15.3 | 57.25 | -64.64 | 3.54 | -11.73 | Upgrade
|
| Legal Settlements | - | - | -8,011 | - | - | - | Upgrade
|
| Other Unusual Items | -5,235 | -9,010 | 351.99 | -2,609 | 445.45 | 328.76 | Upgrade
|
| Pretax Income | 9,444 | 364.95 | 2,398 | 14,412 | 13,825 | 10,961 | Upgrade
|
| Income Tax Expense | 19,379 | 18,673 | 3,294 | 4,476 | 4,124 | 3,201 | Upgrade
|
| Earnings From Continuing Operations | -9,935 | -18,309 | -895.61 | 9,936 | 9,701 | 7,760 | Upgrade
|
| Earnings From Discontinued Operations | 1,431 | 3,973 | 4,670 | - | - | - | Upgrade
|
| Net Income to Company | -8,504 | -14,335 | 3,774 | 9,936 | 9,701 | 7,760 | Upgrade
|
| Minority Interest in Earnings | -248.11 | -681.46 | -801.55 | -519.38 | -0.5 | - | Upgrade
|
| Net Income | -8,752 | -15,017 | 2,972 | 9,417 | 9,700 | 7,760 | Upgrade
|
| Net Income to Common | -8,752 | -15,017 | 2,972 | 9,417 | 9,700 | 7,760 | Upgrade
|
| Net Income Growth | - | - | -68.44% | -2.92% | 25.01% | -16.11% | Upgrade
|
| Shares Outstanding (Basic) | 282 | 282 | 282 | 282 | 282 | 282 | Upgrade
|
| Shares Outstanding (Diluted) | 282 | 282 | 282 | 282 | 282 | 282 | Upgrade
|
| Shares Change (YoY) | 0.04% | 0.00% | - | - | - | -0.00% | Upgrade
|
| EPS (Basic) | -31.01 | -53.22 | 10.53 | 33.37 | 34.38 | 27.50 | Upgrade
|
| EPS (Diluted) | -31.01 | -53.22 | 10.53 | 33.37 | 34.38 | 27.50 | Upgrade
|
| EPS Growth | - | - | -68.43% | -2.93% | 25.01% | -16.11% | Upgrade
|
| Free Cash Flow | -20,772 | -11,638 | 176.29 | 3,185 | 3,565 | 4,610 | Upgrade
|
| Free Cash Flow Per Share | -73.60 | -41.24 | 0.62 | 11.29 | 12.63 | 16.34 | Upgrade
|
| Dividend Per Share | - | 2.500 | 2.500 | 2.500 | 2.500 | 2.500 | Upgrade
|
| Dividend Growth | - | 0% | 0% | 0% | 0% | 25.00% | Upgrade
|
| Gross Margin | 66.56% | 63.79% | 62.16% | 63.04% | 64.85% | 63.89% | Upgrade
|
| Operating Margin | 13.62% | 11.43% | 9.76% | 14.95% | 15.68% | 12.18% | Upgrade
|
| Profit Margin | -6.69% | -11.88% | 2.55% | 7.65% | 8.86% | 7.28% | Upgrade
|
| Free Cash Flow Margin | -15.88% | -9.20% | 0.15% | 2.59% | 3.26% | 4.33% | Upgrade
|
| EBITDA | 20,944 | 18,297 | 14,289 | 19,124 | 19,448 | 14,906 | Upgrade
|
| EBITDA Margin | 16.01% | 14.47% | 12.26% | 15.54% | 17.77% | 13.99% | Upgrade
|
| D&A For EBITDA | 3,128 | 3,840 | 2,907 | 723.93 | 2,287 | 1,922 | Upgrade
|
| EBIT | 17,816 | 14,457 | 11,382 | 18,400 | 17,160 | 12,984 | Upgrade
|
| EBIT Margin | 13.62% | 11.43% | 9.76% | 14.95% | 15.68% | 12.18% | Upgrade
|
| Effective Tax Rate | 205.21% | 5116.71% | 137.34% | 31.06% | 29.83% | 29.20% | Upgrade
|
| Revenue as Reported | 131,371 | 126,531 | 118,721 | 124,716 | 109,941 | 108,006 | Upgrade
|
| Advertising Expenses | - | 5,157 | 5,270 | 4,349 | 4,287 | 5,698 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.